These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31165405)

  • 21. Booster dose after 10 years is recommended following 17DD-YF primary vaccination.
    Campi-Azevedo AC; Costa-Pereira C; Antonelli LR; Fonseca CT; Teixeira-Carvalho A; Villela-Rezende G; Santos RA; Batista MA; Campos FM; Pacheco-Porto L; Melo Júnior OA; Hossell DM; Coelho-dos-Reis JG; Peruhype-Magalhães V; Costa-Silva MF; de Oliveira JG; Farias RH; Noronha TG; Lemos JA; von Doellinger Vdos R; Simões M; de Souza MM; Malaquias LC; Persi HR; Pereira JM; Martins JA; Dornelas-Ribeiro M; Vinhas Ade A; Alves TR; Maia Mde L; Freire Mda S; Martins Rde M; Homma A; Romano AP; Domingues CM; Tauil PL; Vasconcelos PF; Rios M; Caldas IR; Camacho LA; Martins-Filho OA
    Hum Vaccin Immunother; 2016; 12(2):491-502. PubMed ID: 26360663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination.
    Sandberg JT; Ols S; Löfling M; Varnaitė R; Lindgren G; Nilsson O; Rombo L; Kalén M; Loré K; Blom K; Ljunggren HG
    J Immunol; 2021 Aug; 207(4):1033-1043. PubMed ID: 34321231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients.
    Wieten RW; Goorhuis A; Jonker EFF; de Bree GJ; de Visser AW; van Genderen PJJ; Remmerswaal EBM; Ten Berge IJM; Visser LG; Grobusch MP; van Leeuwen EMM
    J Infect; 2016 Jun; 72(6):713-722. PubMed ID: 27017899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.
    Campi-Azevedo AC; Reis LR; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Antonelli LR; Fonseca CT; Costa-Pereira C; Souza-Fagundes EM; da Costa-Rocha IA; Mambrini JVM; Lemos JAC; Ribeiro JGL; Caldas IR; Camacho LAB; Maia MLS; de Noronha TG; de Lima SMB; Simões M; Freire MDS; Martins RM; Homma A; Tauil PL; Vasconcelos PFC; Romano APM; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA
    Front Immunol; 2019; 10():2192. PubMed ID: 31616412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology.
    Pulendran B
    Nat Rev Immunol; 2009 Oct; 9(10):741-7. PubMed ID: 19763148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The early cellular signatures of protective immunity induced by live viral vaccination.
    Kohler S; Bethke N; Böthe M; Sommerick S; Frentsch M; Romagnani C; Niedrig M; Thiel A
    Eur J Immunol; 2012 Sep; 42(9):2363-73. PubMed ID: 22733156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection
    Douam F; Soto Albrecht YE; Hrebikova G; Sadimin E; Davidson C; Kotenko SV; Ploss A
    mBio; 2017 Aug; 8(4):. PubMed ID: 28811340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T Cells.
    Watson AM; Lam LK; Klimstra WB; Ryman KD
    PLoS Pathog; 2016 Jul; 12(7):e1005786. PubMed ID: 27463517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mathematical modeling provides kinetic details of the human immune response to vaccination.
    Le D; Miller JD; Ganusov VV
    Front Cell Infect Microbiol; 2014; 4():177. PubMed ID: 25621280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multi-parameter approach to evaluate the timing of memory status after 17DD-YF primary vaccination.
    Costa-Pereira C; Campi-Azevedo AC; Coelho-Dos-Reis JG; Peruhype-Magalhães V; Araújo MSS; do Vale Antonelli LR; Fonseca CT; Lemos JA; Malaquias LCC; de Souza Gomes M; Rodrigues Amaral L; Rios M; Chancey C; Persi HR; Pereira JM; de Sousa Maia ML; Freire MDS; Martins RM; Homma A; Simões M; Yamamura AY; Farias RHG; Romano APM; Domingues CM; Tauil PL; Vasconcelos PFC; Caldas IR; Camacho LA; Teixeira-Carvalho A; Martins-Filho OA
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006462. PubMed ID: 29879134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymphocyte subset analyses in healthy adults vaccinated with yellow fever 17DD virus.
    Santos AP; Bertho AL; Dias DC; Santos JR; Marcovistz R
    Mem Inst Oswaldo Cruz; 2005 May; 100(3):331-7. PubMed ID: 16113878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice.
    Kum DB; Boudewijns R; Ma J; Mishra N; Schols D; Neyts J; Dallmeier K
    Emerg Microbes Infect; 2020; 9(1):520-533. PubMed ID: 32116148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil.
    Campi-Azevedo AC; Peruhype-Magalhāes V; Coelho-Dos-Reis JG; Antonelli LR; Costa-Pereira C; Speziali E; Reis LR; Lemos JA; Ribeiro JGL; Bastos Camacho LA; de Sousa Maia ML; Barbosa de Lima SM; Simões M; de Menezes Martins R; Homma A; Cota Malaquias LC; Tauil PL; Costa Vasconcelos PF; Martins Romano AP; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
    Emerg Infect Dis; 2019 Aug; 25(8):1511-1521. PubMed ID: 31298654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of Novel Yellow Fever Class II Epitopes in YF-17D Vaccinees.
    Mateus J; Grifoni A; Voic H; Angelo MA; Phillips E; Mallal S; Sidney J; Sette A; Weiskopf D
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33198381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human immune memory to yellow fever and smallpox vaccination.
    Wrammert J; Miller J; Akondy R; Ahmed R
    J Clin Immunol; 2009 Mar; 29(2):151-7. PubMed ID: 19052852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Human NK Cell Response to Yellow Fever Virus 17D Is Primarily Governed by NK Cell Differentiation Independently of NK Cell Education.
    Marquardt N; Ivarsson MA; Blom K; Gonzalez VD; Braun M; Falconer K; Gustafsson R; Fogdell-Hahn A; Sandberg JK; Michaëlsson J
    J Immunol; 2015 Oct; 195(7):3262-72. PubMed ID: 26283480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.
    Jiang X; Dalebout TJ; Lukashevich IS; Bredenbeek PJ; Franco D
    J Gen Virol; 2015 Apr; 96(Pt 4):804-814. PubMed ID: 25516543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice.
    van der Most RG; Harrington LE; Giuggio V; Mahar PL; Ahmed R
    Virology; 2002 Apr; 296(1):117-24. PubMed ID: 12036323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical evidence for the immunogenicity and immune persistence of vaccination with yellow fever virus strain 17D in Chinese peacekeepers deployed to Africa.
    Jia Q; Jia C; Liu Y; Yang Y; Qi J; Tong L; Chen H; Zhang M; Che J; Li B; Li Z
    Antiviral Res; 2019 Feb; 162():1-4. PubMed ID: 30529359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein structure shapes immunodominance in the CD4 T cell response to yellow fever vaccination.
    Koblischke M; Mackroth MS; Schwaiger J; Fae I; Fischer G; Stiasny K; Heinz FX; Aberle JH
    Sci Rep; 2017 Aug; 7(1):8907. PubMed ID: 28827760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.